Markus Thomas Rojewski

List of Publications by Year
in descending order

29	1,138	623734	580821
papers	citations	14 h-index	25 g-index

30	30	30	2157
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy, 2012, 14, 540-554.	0.7	246
2	TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin Wounds. Journal of Investigative Dermatology, 2014, 134, 526-537.	0.7	195
3	Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. Stem Cell Research and Therapy, 2018, 9, 213.	5.5	132
4	Standardization of Good Manufacturing Practiceâ€“compliant production of bone marrowâ€“derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 2015, 17, 128-139.	0.7	118
5	Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials, 2019, 196, 100-108.	11.4	87
6	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. Journal of Infectious Diseases, 2021, 223, 796-801.	4.0	51
7	The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. Experimental Hematology, 2003, 31, 815-823.	0.4	41
8	S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes. Journal of Immunology, 2014, 192, 6102-6110.	0.8	35
9	Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. Cytotherapy, 2019, 21, 468-482.	0.7	33
10	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. Cancer Research, 2018, 78, 129-142.	0.9	32
11	Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. Injury, 2020, 51, S63-S73.	1.7	32
12	Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells. FEBS Letters, 2004, 578, 85-89.	2.8	23
13	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19â€“Convalescent Donors. Journal of Immunology, 2021, 206, 2614-2622.	0.8	22
14	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic <scp>T</scp> cells against immunogenic leukemiaâ€associated antigens. International Journal of Cancer, 2015, 137, 2083-2092.	5.1	19
15	Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration. International Journal of Molecular Sciences, 2018, 19, 2526.	4.1	15
16	Osteoarthritic Milieu Affects Adiposeâ€Derived Mesenchymal Stromal Cells. Journal of Orthopaedic Research, 2020, 38, 336-347.	2.3	13
17	ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase. Immunity, Inflammation and Disease, 2018, 6, 448-455.	2.7	11
18	Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model. Cytotherapy, 2018, 20, 218-231.	0.7	9

#	Article	IF	Citations
19	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. Blood, 2007, 110, 1806-1806.	1.4	9
20	Transduction Enhancers Enable Efficient Human Adenovirus Type 5-Mediated Gene Transfer into Human Multipotent Mesenchymal Stromal Cells. Viruses, 2021, 13, 1136.	3.3	4
21	Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. Oncology Reports, 0, , .	2.6	3
22	CD90 Is Dispensable for White and Beige/Brown Adipocyte Differentiation. International Journal of Molecular Sciences, 2020, 21, 7907.	4.1	2
23	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 3159-3159.	1.4	2
24	Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells. Molecular Therapy - Methods and Clinical Development, 2022, 25, 96-110.	4.1	2
25	The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells. Current Signal Transduction Therapy, 2009, 4, 222-233.	0.5	1
26	Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia. Blood, 2011, 118, 4997-4997.	1.4	1
27	Corrigendum to: Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)- and anti-CD95-induced apoptosis in myeloid cells (FEBS 29005) [FEBS Letters 578 (2004) 85-89]. FEBS Letters, 2005, 579, 3866-3866.	2.8	0
28	Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.. Blood, 2006, 108, 2201-2201.	1.4	0
29	RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.. Blood, 2006, 108, 409-409.	1.4	0